Financial Survey: RedHill Biopharma (RDHL) and ProQR Therapeutics (PRQR)

RedHill Biopharma (NASDAQ: RDHL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Risk and Volatility

RedHill Biopharma has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

9.0% of RedHill Biopharma shares are held by institutional investors. Comparatively, 32.2% of ProQR Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares RedHill Biopharma and ProQR Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RedHill Biopharma $100,000.00 1,184.74 -$29.37 million N/A N/A
ProQR Therapeutics N/A N/A -$43.27 million ($1.90) -1.64

RedHill Biopharma has higher revenue and earnings than ProQR Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for RedHill Biopharma and ProQR Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RedHill Biopharma 0 0 5 0 3.00
ProQR Therapeutics 0 1 3 0 2.75

RedHill Biopharma currently has a consensus target price of $23.60, indicating a potential upside of 323.70%. ProQR Therapeutics has a consensus target price of $24.00, indicating a potential upside of 669.23%. Given ProQR Therapeutics’ higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than RedHill Biopharma.

Profitability

This table compares RedHill Biopharma and ProQR Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RedHill Biopharma N/A -85.09% -67.92%
ProQR Therapeutics N/A -97.68% -75.50%

Summary

RedHill Biopharma beats ProQR Therapeutics on 7 of the 10 factors compared between the two stocks.

RedHill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply